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Abstract
Purpose The incidence of adverse drug events (ADE) is an
important parameter in determining the quality of medical
care. We identified the probability that a specific data
source would identify ADEs in patients on the oncology
ward, that could be assigned to one substance.
Methods We captured all medical adverse events (AE) from
five different data sources. Each AE was determined to be
drug-related according to the WHO criteria and classified
according to the severity, category, and causality of the ADE.
Results The study recorded 129 patients with 252
hospitalizations over a 5-month period. A total of 3,341
medical events were captured and resulted in 1,121
ADEs. In 122 patients, at least one ADE (95%) was
observed. Only 39 hospitalizations were believed not to
have an ADE (15%). No ADE was captured by all data
sources. The patient record captured 550, the nursing
record 569, the laboratory tests 387, the questionnaire 63,
and the event monitoring during grand rounds 141
ADEs. Only the nursing record and the laboratory tests
had a significantly different probability of observing
indicative ADEs.
Conclusion For all AEs reported in the data sources,
physicians and nurses were the best source for ADEs. Data
sources differed in identifying indicative ADEs and were
influenced by specific patient parameters.
Keywords Adverse drug event . Chemotherapy .
Oncology .Monitoring . Data sources
Introduction
At the time of drug registration, a comprehensive safety
profile is often not available for patients with multiple risk
factors [1]. After market authorization, the spontaneous
reporting system records serious and unknown adverse drug
events (ADE) and enhances the existing safety profile.
However, this type of data allows no reliable estimation of
the frequency of ADEs [2] because not all ADEs are
reported. Epidemiological studies can determine the inci-
dence of ADEs and provide further information on
causality, preventability, and costs for the health care
system. All available data sources have to be monitored
and analyzed if all ADEs are to be captured. More data
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sources [3] or better algorithms for detection result in a
higher incidence of captured ADEs [4, 5].
Variations in the number of data sources, detection
methods, and variations in study populations have a major
impact on the reported incidence of ADEs [6]. A meta-
analysis of Lazarou et al. has been controversially discussed
because of the variability within 39 included studies. But
this controversy can not cloud the fact that ADEs ranked as
the fourth to sixth leading cause of death in the U.S. [7]. A
prospective cohort study in Switzerland reported clinically
relevant ADEs in 11% of all hospitalizations on the internal
ward [8], but the patients with chemotherapy had a higher
incidence due to the cytotoxic properties and low therapeutic
range of the agents. Additional risk factors include morbidity,
sex, age, unknown co-medication, and noncompliance
[9–11]. Even the reported risk in a seemingly homoge-
neous population on the oncology ward ranges from 5.0
and 74.3% [12, 13]. Common ADEs caused by chemo-
therapy are hematological problems, opportunistic infec-
tions, signs of cardiac toxicity, nausea or vomiting, skin
reactions, stomatitis, alopecia, fatigue, constipation, and
diarrhea [13, 14]. A portion of these ADEs are preventable
[13, 14], though published protocols differ in dosage,
duration of treatment, and applied cycles. Ambiguous
information in the literature concerning the correct
administration of the drugs can impair reproducibility
[15] and reduce the effectiveness of therapy, which results
in increased hospital days and reduced life span [16].
Additional hospital days add major costs to the health care
system [17]. A British study estimated additional costs of
about 706 million EUR per year for the National Health
Service with a 6.5% incidence of ADEs [18]. The U.S.
estimated extra costs total $17 billion to $29 billion per
year [19]. These extra costs may be reduced by supportive
therapy or improved monitoring of ADEs [20]. Avoiding
ADEs has great potential. A British study defined 72% of
the ADEs as preventable [18].
We monitored the ADEs of hospitalized patients in two
oncology wards of the University Hospital Zurich over a
period of 5 months (April through September 2008) and
determined the probability that a specific data source would
identify an indicative ADE in the hospitalized patient and
whether patient-specific parameters were relevant.
Methods
Study population
We monitored the ADE of hospitalized patients on two
oncology wards over a period of 5 months (April through
September 2008) and calculated the probability that a
specific data source would identify an indicative ADE.
Ethics approvals (EK-1488) for this study were obtained
from the Clinical Research and Ethics Committee at the
University Hospital Zurich and University of Zurich. We
included all inpatients who were 18 years or older at the
time of admission to the oncology wards “G-West” and
“H-West” of the University Hospital Zurich between
April and September 2008 and signed the informed
consent. We did not exclude any patients.
Adverse drug event
According to the WHO an adverse event (AE) is defined as
“any untoward medical occurrence that may present during
treatment with a pharmaceutical product but which does not
necessarily have causal relationship with this treatment”
and an adverse drug reaction (ADR) as “any noxious,
unintended and undesired effect of a drug that occurs at
doses used in humans for prophylaxis, diagnosis or therapy
of disease or for the modification of physiologic function.”
ADRs and AEs due to medication errors are defined as
ADEs or any “injury resulting from medical intervention
related to a drug” [21]. Therefore ADEs also include errors
in administration, non-compliance, therapeutic failures, and
accidental poisoning.
Causality
The causality assessment was based on the classification of
the WHO Uppsala Monitoring Centre and comprised the
categories “certain,” “probable,” “possible,” “unlikely,” “con-
ditional/unclassified,” and “other.” The temporal relationship
of the use of the drug, the plausibility, and the likelihood of
alternative causes was taken into account in the identification
of an ADE. In this study, the causality terms “unlikely,”
“conditional/unclassified,” and “unassessable/unclassifiable”
were grouped under the term “unlikely” (Fig. 1). The study
physician collected all AEs and assessed the causality and
severity after data closure. The investigator reviewed the
cases. Special or complicated cases were discussed, and
resolutions were reached unanimously. An ADE was
considered an indicative ADE if the causality was probable
or certain and the ADE could be assigned specifically to one
substance.
Severity
The classification of the severity is derived from the
Common Terminology Criteria for Adverse Events v3.0
(CTCAE) and includes five grades (grade 1: mild AE;
grade 2: moderate AE; grade 3: severe AE; grade 4: life-
threatening or disabling AE; and grade 5: death related to
AE) [22]. Grades 3 to 5 of the CTCAE correspond to the
definition of a serious ADE by the WHO (results in death,
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requires inpatient hospitalization or prolongation of existing
hospitalization, results in persistent or significant disability/
incapacity, life-threatening). The CTCAE lists the possible
AEs that may occur during chemotherapy. The AEs of the
CTCAE are derived from theMedDRA terminology (Medical
Dictionary For Regulatory Activities), which in turn integrates
the terminology of the WHO-ART (WHO – Adverse
Reactions Terminology). The MedDRA terminology is
currently accepted by the European Union, the U.S., and
Japan for the reporting of AEs.
Data sources
Medical events were collected regardless of possible
relationships to a potential drug treatment to ensure the
detection of a large number of ADEs that were not initially
detected and incorrectly, unwittingly, or spontaneously
attributed to a different cause.
Monitoring on the ward round
All AEs that were communicated verbally by the medical
staff at the regular ward rounds were written down by the
accompanying study physician on a data entry form. These
AEs were recorded in order to detect possible ADEs that
were not declared as such in writing in the medical
documentation, due to falsely assumed lack of relevance.
Manual review of medical records
All AEs from the paper-based medical documentation of
the patients were copied. The medical documentation
consisted of the medical report, medical history, lab results,
consultations, nursing report, and patient charts. The
nursing documentation provided the necessary additional
information on the entire medication, including time and
date of administration and dosage.
Laboratory values
Values above or below the normal range (reference values
from the University Hospital Zurich) were documented as
an AE by the study physician after monitoring all lab
values. Values outside the normal range with no pathological
meaning were not considered as an AE.
Patient questionnaire
Each patient hospitalized on the oncology ward received a
questionnaire after signing the informed consent that
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Fig. 1 Flowchart visualizing
the algorithm for rating the
causality of a drug based on the
WHO classification
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inquired about possible co-medications, use of phytotherapy,
consumptions of fruit juices, and the current general condition.
The morbidity was rated according to the Karnofsky index.
The patient received an additional questionnaire from the study
physician at each following hospitalization regarding any AEs
experienced at home prior to the current hospitalization. The
questionnaire was designed to be a sensitive surrogate
parameter in case many patients were discharged from the
hospital before the onset of ADEs.
Statistical methods
Data collection
The data were recorded in a Microsoft Access 2003
database. Relevant patient data, such as laboratory values
or medical documentation, were imported into the database.
Paper-based patient data, such as questionnaires or inpatient
medical records and patient charts, were copied and
archived. All recorded AEs in the observation period were
documented. For the mapping of data in the database,
patients were linked relationally to the hospitalizations, and
the hospitalizations to the AE in a “1−n” relationship.
Data analysis
We performed queries within the database and extracted
data into Excel spreadsheets. We used Talend Open Studio
(version 3.04) to extract, transform, and analyze the data
with SPSS. For descriptive statistics, transformation of
skewed distribution and linear regression, we applied SPSS
(version 17.02), and for the control of clustering at the
patient level, we used STATA (version 10). For all analyses,
a P-value <0.05 was considered to be significant.
Descriptive statistics
The patient population was described according to
patient characteristics, number of hospitalizations, and
the ADE-related hospitalizations, as well as reasons for
hospitalization excluding chemotherapy. Diagnoses were
grouped by organ systems, and medical therapy was
described by a descending list of the total treatment days
of each chemotherapeutic agent with a cumulative 90%
cut off (DU90) [23]. ADEs were classified according to
organ systems, causality, and severity. The predictability
of ADEs was listed in a frequency table. Descriptive
patient characteristics (BMI, age, general condition,
hospital stay, and number of drugs) were evaluated with
mean, standard deviation (SD), median, first quartile (Q1),
third quartile (Q3), and interquartile range (IQR). Patient
characteristics and the diagnosis groups were analyzed
according to the frequency and causality of ADEs.
Medication was evaluated according to drug utilization
and causality of the ADEs. The expected (calculated)
values were compared with the observed values (frequencies).
The significance was calculated by using a chi-squared test.
Regression analysis
We assessed the performance of the data sources with respect
to detection of ADEs in relation to the binary target variable
“possible ADE detected” and “certain or probable ADE
detected” using logistic regression and the associated odds
ratio (OR) with its 95% confidence interval (CI). The results
were shown in tables. AVenn diagram illustrates the overlap
of ADEs for the categories “patient record,” “laboratory,”
and “nursing record.” Next, we noted whether patient
characteristics influenced the performance of the data
sources. We used univariate regression and defined the
data sources “patient record,” “nursing report,” “laboratory,”
“monitoring,” and “questionnaire” as the dependent variable
and the patient characteristics [gender, BMI, chemo-naive,
general condition, log(hospitalization), number of drugs,
chemotherapy (yes/no), number of ADEs, severity, causality,
ADE-related hospitalization, diagnosis of malignancy, and
category ofADE by organ system] as the independent variable.
After finding the optimal model for the univariate logistic
regression, we used STATA to correct for clustering. The
duration of hospital staywas transformed using the logarithmic
function due to a skewed distribution. We developed the
optimal model using Enter, Forward, and Backward proce-
dures for every dependent variable. The discriminator of the
multiple logistic regressions was expressed with ROC curves
and with the AUC (area under the ROC curve).
We corrected the clustering for different numbers of
hospitalizations per patient with the procedure “logit”
and the option “vce” (Cluster) in STATA. The bivariate
Spearman’s correlation was tested if the covariates of the
optimal model correlated with each other.
Results
During the observation period, 81 male and 48 female
patients were monitored during 252 hospital admissions.
The median (Q1, Q3) age was 57 (44, 63) years and the
median BMI 23.6 (20.8, 26.6). The median Karnofsky
index was 80 (70, 80) and the median duration of
hospitalization 5 (3, 8) days. Seventy-two patients were
recorded with a single hospitalization (n=72) and 57
patients with multiple hospitalizations (n=180). The median
number of all substances per hospitalization was 10 (8, 14)
consisting of 2 (2,3) chemotherapeutic, 3 (3,4) supportive,
and 4 (2,8) concomitant agents. Chemotherapy was not
administered in 39 hospitalizations.
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The admission of the patient was due to an ADE in 14
cases, palliative therapy in 4 cases, further medical examina-
tions in 6 cases, stem cell apheresis in 7 cases, and other
reasons in 8 cases. Forty-three of the 129 patients received a
cytotoxic drug for the first time and were labelled “chemo-
naive.” Sixty-eight patients had already been under treatment
and were labelled “chemo-experienced.” A total of 129
patients refused or were not able to give informed consent.
A total of 25 hospitalizations (9.2% of all hospitalizations)
were ADE-related. In some cases, the scheduled chemo-
therapy could be continued in these hospitalizations due
to the improved general condition of the patient. The
most frequent cause of an admission was a severe ADE
from the category gastrointestinal symptoms or infectious
diseases. Most common sites of malignancy were the
lymphatic system (27%), lung (23%), and gastrointestinal
system (13%). Other groups were head/neck (9%), CNS
(6%), urology (6%), hematology (6%), sarcoma (4%),
breast (4%) and other (2%). The applied 214 substances
consisted of 42 chemotherapeutic agents, 14 supportive
agents, and 158 concomitant substances. Besides the
chemotherapeutic agents, only morphine and dexamethasone
had a frequent use. Of the chemotherapeutic agents, a mere 18
substances contributed to more than 90% of treatment days.
Adverse drug events
A total of 3,341 AEs were recorded and 1,121 distinct
ADEs were identified in all data sources. Most ADEs were
mild in severity (67%) or rated with causality “possible”
(68%). Only one-third of the ADEs were assessed with
causality “probable” or “certain” and were rated indicative
Gastrointestinal
ADE - Category
30.33%
Metabolic/Laboratory
Infection
Haematological
11.24%
11.33% 21.68%
Nervous system
Cardiovascular 6.07%
5.44%
Dermatology/Skin
Constitutional symptoms
mild 
moderate3.75%
5.26%
Pulmonary/Upper Respiratory
Miscellaneous
Special senses severe
life-threatening
death0.89%
1.69%
1.69%
0 50 100 150 200 250 300 350
Renal/Genitourinary 0.62%
Number of ADE (n = 1121)
1.69%
3.75%
5.26%
Fig. 2 Percentage of ADEs for each ADE category. Each category is subdivided according to the severity rating of the ADE
Table 1 Characteristics of patients with ADE
Parameter Median IQR Mean SD Missing
BMI 4.23 9.4 24 4.3 4
Age (years) 59 13 53.8 2.14 0
Karnofsky index 70 10 75.1 4.14 92
Hospital stay (days) 13.0 20 4.18 19.0 0
All drugs (n) 15.0 13 17.0 9.0 0
IQR Interquartile range, SD standard deviation, BMI body mass index,
n number
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ADEs. Only 0.4% of ADEs were assessed “certain” after de-
and re-challenge. The ADEs were mostly predictable and
well-known for the substance. Uncommon types of reactions
included a morphine-withdrawal syndrome and two cases of
allergic reactions. The disease was the underlying cause in
2,220 AEs. The median number of ADEs was 3 (1, 5) ADEs
per hospitalization and 6 (3, 13) per patient (irrespective of the
number of hospitalizations). No ADEs were seen in 39
hospitalizations. A total of 122 of 129 patients experienced at
least one ADE. The most common ADEs were gastrointes-
tinal and hematological ADEs (Fig. 2).
Patient characteristics of ADEs are shown in Table 1.
The characteristics female gender and “chemo-naive”
occurred in 38 and 14% of ADEs, respectively.
Of the 214 different substances, 112 substances (2,207
products) caused ADEs. Thirty-two substances were respon-
sible for 91% of ADEs and the remaining 80 substances
caused the remaining 9% of ADE. One ADE could be caused
by more than one substance. The chemotherapeutic agents,
which caused 73% of ADEs, are listed in Table 2.
Performance of data sources
The data sources “patient record,” “nursing record,”
“laboratory,” “monitoring,” and “questionnaires” were
compared according to their ability to capture indicative
ADEs. The three major data sources that captured most of the
ADEs are shown in Fig. 3. The data sources “questionnaires”
and “monitoring” captured only 34 additional ADEs. Of
these ADEs the “questionnaires” captured 23 of 87 and
Substance Days of use Hosp. ADE
Number Percentage Number Number Pro Pos
Etoposide 214 19 54 193 183 10
Cisplatin 140 12 87 247 37 210
Cytarabine 135 12 37 125 9 116
Fluorouracil 117 10 30 138 12 126
Cyclophosphamide 69 6 39 79 1 78
Doxorubicin 50 4 34 87 20 67
Ifosfamide 42 4 19 48 2 46
Vincristin 41 4 30 67 3 64
Capecitabine 40 4 3 13 2 11
Rituximab 40 4 38 55 15 40
Carboplatin 27 2 25 78 14 64
Gemcitabine 27 2 23 69 12 57
Docetaxel 25 2 23 123 14 109
Melphalane 22 2 18 154 46 108
Methotrexate 19 2 13 9 0 9
Epirubicine 18 2 6 13 2 11
Carmustine 13 1 13 97 7 90
Fludarabine 12 1 4 5 0 5
DU90% 1,051 91 496
Other 106 9 78
Total 1,157 100 574 1,600 379 1,221
Table 2 Utilization of
chemotherapy agents
Pro Probable, Pos possible, n
number, Hosp hospitalization
254
Nursing care record (n=569)
Patient medical record (n=550)
Laboratory (n=387)
255191
35
2569
258
Fig. 3 Venn diagram with the best performing data sources. If an
ADE was captured by more than one data source, the count is
displayed at the intersections. The three data sources captured 1,087
distinct ADEs from a total of 1,121 distinct ADEs
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“monitoring” 10 of 152 alone. Only one ADE was captured
by both sources simultaneously. No ADE was captured by
all data sources.
Relevant for the performance is the sensitivity and
specificity of the data sources, which were tested using a
cross table and logistic regression. Of 1,121 ADEs, only
353 (32%) had the causality “probable” or “certain” and
were considered relevant information. The “nursing record”
alone captured 31% of the indicative ADEs, which was
significantly higher than expected. We calculated 80
indicative ADEs and observed 109. In contrast, we
calculated 81 indicative ADEs for the “laboratory,” but
observed 41. The “patient record” closely matched the
calculated values with expected 60 and observed 65 ADEs,
and the data sources “monitoring” and “questionnaire”
exactly matched the calculated numbers. We confirmed the
findings with logistic regression, and results are shown in
Table 3. “Laboratory” shows a negative influence on the
capturing of indicative ADEs with beta −0.9, OR 0.394,
and P-value<0.001. The “nursing record” increased the
probability of capturing indicative ADEs with beta 0.7 and
OR 2. The other data sources were not significantly better
or worse at capturing indicative ADEs.
Patient characteristics also influenced the performance of
the data sources. In order to identify the respective patient
parameter for the groups “neoplasm diagnosis” and “ADE
category,” we defined a baseline using the most common
parameters “lymphoma” and “gastrointestinal,” respectively.
Patient parameters that were found to have a statistically
significant influence on the performance of the data sources
are shown in Tables 4, 5, and 6.
Discussion
Many studies [7, 8, 17, 18] have reported on the incidence
and category of ADEs. In order to be comparable, we also
report the standard evaluation and analysis of ADEs and
drugs. Detailed information [12, 15, 16] on ADEs in
oncology has been rarely published. Our study focuses
primarily on the performance of different data sources in
capturing ADEs, similarly to the study of Classen [4]. In
addition we also took the influence of the patient’s specific
parameters on the performance of data sources into account
and calculated the probability of each data source to detect
indicative ADEs.
In oncology the delayed appearance of ADEs is a problem.
Some ADEs only occur after discharge [24], and the
questionnaires captured the interval between hospitalizations.
We did not expect added value during hospital stay, but our
results support the conclusion of Basch and Weingart, who
proposed regular patient diaries as an important additional
data source in patients with chemotherapeutic therapy [25].
However, the use of questionnaires for patients with a
Data source Beta P-value Odds ratio (adj. OR) 95% CI (adj. OR)
Patient record 0.229 0.076 1.257 0.976, 1.618
Nursing record 0.703 <0.001 2.021 1.561, 2.616
Laboratory −0.931 <0.001 0.394 0.294, 0.528
Monitoring −0.128 0.504 0.880 0.604, 1.281
Questionnaire 0.110 0.643 1.116 0.701, 1.779
Table 3 Multiple logistic
regression of the performance of
the data sources
Adj. OR Adjusted odds ratio,
95% CI 95% confidence interval
Parameter Beta P-value Adj. OR 95% CI (adj. OR)
Log(hospital stay) 0.215 0.014 1.239 1.044, 1.472
Severity of ADE 0.490 <0.001 1.632 1.329, 2.005
Cause of hospitalization 1.829 0.004 1.803 1.802, 21.536
Neoplasm diagnosis 0.767 0.06 2.154 0.967, 4.796
Gastrointestinal −0.275 0.634 0.759 0.244, 2.358
Head/neck 0.841 0.085 2.320 0.890, 6.043
Pulmonary 0.169 0.691 1.185 0.514, 2.728
ADE category −0.859 0.017 0.423 0.220, 0.856
Dermatology 0.279 0.572 1.321 0.503, 3.469
Hematology −2.248 < 0.001 0.106 0.049, 0.225
Metabolic −2.054 < 0.001 0.128 0.054, 0.303
Special senses 0.706 0.341 2.026 0.474, 8.654
Table 4 Multiple logistic
regression of optimal model
“patient record” with ADEs
(n=1,025)
Adj. OR Adjusted odds ratio,
95% CI 95%
confidence interval
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potentially fatal disease can confer a high psychological
burden. Fattinger et al. [8] reported at least one clinically
relevant ADE in one-third of all hospitalizations with
chemotherapy. In this study, ADEs were found in 213
(85%) hospitalizations. Chemotherapeutic agents caused 889
(79%), concomitant therapy 223 (20%), and supportive
therapy 95 (8%) of the total of 1,121 ADEs. Cisplatin was
a common chemotherapeutic agent and caused most of the
ADEs as listed in Table 2. Dexamethasone from the group of
supportive therapy and morphine from the group of
concomitant therapy caused the most ADEs in the respective
subgroups. The incidence of ADEs was not normalized for
the prescription frequencies.
The performance of data sources is hampered by the
missing use of standards and the lack of discrimination
between relevant and irrelevant information. The heteroge-
neity of data collection and nonstandardized assessment
methods in previous studies interfere with the extraction of
relevant information [6].
In previous studies in oncology the incidence of ADEs
has ranged widely from 5.0 to 74.3%, depending on the
patients and methods used [12–14]. We captured at least
one ADE in more than 95% of the patients but found
indicative information in only 30% of the ADEs. We
observed the causality “certain” in only 0.4% of the ADEs.
The low result is explained by the missing re-challenge in
daily clinical practice, which is only feasible if no
alternative therapy is available. We did not discover any
yet unknown ADEs. In order to capture the maximum
number of ADEs, all data sources have to be considered
[3]. No one data source detected all 1,121 ADEs in our
study. Even the most sensitive data sources “patient record”
and “nursing record” captured only 49 and 51% of all
ADEs, respectively. Therefore no data sources can be
omitted because each has unique information. “Patient
record,” “nursing record,” and “laboratory” captured 1,087
of 1,121 ADEs, but captured only 35 concurrent ADEs. In
addition the data sources each provided a different degree
of structured information. The “nursing record” has a large
amount of detailed free text as compared to the “patient
record,” which contains a very succinct summary of the
information. The “laboratory” is structured, but values were
considered as an ADE if outside the normal range and were
not adapted to the special clinical situation in chemotherapy.
“Monitoring” on ward rounds provided added value but was
limited by the fact that the data also occurred in the “patient
record.” On the ward many mild to moderate expected and
known ADEs were not specifically mentioned. Observations
Parameter Beta P-value Adj. OR 95% CI (adj. OR)
Log(hospital stay) 0.513 0.001 1.670 1.251, 2.230
No. of drugs 0.047 0.018 1.048 1.008, 1.089
No. of ADE −0.048 0.006 0.953 0.922, 0.986
Indicative ADE 0.565 <0.001 1.760 1.322, 2.343
ADE category 0.455 0.119 1.576 0.889, 2.795
Dermatology −0.517 0.229 0.596 0.257, 1.385
Hematology −2.044 <0.001 0.130 0.063, 0.264
Infection −1.286 <0.001 0.276 0.145, 0.528
Metabolic −3.204 <0.001 0.041 0.018, 0.090
Nervous system −0.277 0.492 0.758 0.345, 1.669
Renal −3.058 0.002 0.047 0.007, 0.328
Special senses −1.877 0.005 0.153 0.041, 0.574
Table 5 Multiple logistic
regression of optimal model
“nursing record” with ADEs
(n=1,121)
Adj. OR Adjusted odds ratio,
95% CI 95% confidence interval
Parameter Beta P-value Adj. OR 95% CI (adj. OR)
No. of drugs −0.051 <0.001 0.950 0.925, 0.976
Severity of ADE 0.435 0.002 1.545 1.167, 2.045
Indicative ADE −0.865 0.022 0.421 0.201, 0.880
Neoplasm diagnosis −0.786 0.161 0.456 0.152, 1.369
Mammary 0.956 0.107 2.601 0.813, 8.322
ADE category −0.789 0.595 0.454 0.025, 8.308
Infection −0.085 0.855 0.918 0.367, 2.298
Metabolic 1.080 0.055 2.944 0.979, 8.855
Table 6 Multiple logistic
regression of optimal model
“laboratory” with ADE
(n=1,121)
Adj. OR Adjusted odds ratio,
95% CI 95% confidence interval
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by the investigator were discarded in order not to bias the
study results. For example, alopecia was regularly observed
by the investigator but was not mentioned in any data sources,
since it had no bearings on clinical practice.
The patient characteristics play an important role in
capturing ADEs. The “patient record” captured more ADEs
if the patient stayed longer in the hospital, experienced a
serious ADE, or if the admission was ADE-related. ADEs
in the categories “hematology” and “metabolic” were not
well perceived because the ADEs often did not require
medical action (Table 4). The “nursing record” was more
influenced by patient parameters. If a patient had a longer
“duration of hospitalization,” a higher “number of drugs,”
or previous ADEs with causality “probable” and “certain”
the next ADE was more likely to be captured. Complex
patients were more closely supervised by the nurses. A
negative impact on the capturing of ADEs in the “nursing
record” was seen with a high number of previous ADEs in
this patient or with an ADE from the categories “hematology,”
“infectiology,” “metabolic,” “renal,” or “special senses”
(Table 5). The “laboratory” primarily captured serious ADEs.
If a patient had serious nausea and vomiting for several days,
the imbalance of electrolytes became evident in the lab.
Therefore lab examinations contained more relevant infor-
mation if a clinical problem preceded. The “monitoring”
captured more ADEs if a patient was older, stayed longer in
the hospital, or was admitted due to an ADE. This closely
resembled the patient characteristics of the “patient record.”
If the patient had never received chemotherapy before, the
probability that a physician recorded the ADE was reduced.
The “questionnaire” captured ADEs in patients, particular if
the patient had a previous chemotherapy, presented a serious
ADE, or was hospitalized due to an ADE. Experiencing an
ADE raised the awareness of the patient. A negative
relationship was seen with the characteristics “chemo-naive”
and “duration of hospitalization.” Apparently the patient
seemed less sensitive to perceiving an ADE before chemo-
therapy but also seemed to tolerate ADEs better in a
prolonged hospital stay. The questionnaires should have
been issued on a daily basis and not at the beginning of the
hospitalization.
Conclusions
The occurrence of ADEs has to be detected and managed to
achieve high quality care. Therefore an efficient method to
capture ADEs is required. The more data sources are used,
the greater the incidence of captured ADEs. For all AEs
reported in the data sources, physicians and nurses are the
best source for ADEs in the oncology ward. Data sources
perform differently at identifying indicative ADEs and are
influenced by specific patient parameters. According to our
study the “nursing record” is an important source for ADEs
and for indicative ADEs. The “patient record” is a
valuable source for serious ADEs and ADEs in complex
patients. The “questionnaire” may have additional infor-
mation but should be issued on a daily basis. Other data
sources such as “laboratory” or electronic information
systems alone are unlikely to discover additional infor-
mation. We provide a rational approach towards identi-
fying the patient’s adverse events that can be assigned
specifically to one cause. The approach should reduce
the clinical complexity of multiple adverse events in
patients with chemotherapy.
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